With their strategic position between RAS-RAF and ERK in the oncogenic MAPK signaling pathway, MEK 1 and 2 are among the most attractive targets for the treatment of a broad range of cancer types (melanoma, thyroid, large part of tumors of the digestive and urogenital systems) carrying RAF or RAS-activating alterations (17–19). The gene discussed is RAF1; the disease is cancer.